Zecotek Releases White Paper on Patented LFS Scintillation Crystal Technology
Singapore, June 14, 2011 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today released a White Paper on its patented (US patent No. 7,132,060) Lutetium Fine Silicate (LFS) series of scintillation crystals. Zecotek’s LFS crystals are distinguished by their radiation hardness, high light yields and ultra-fast fast decay times. These performance advantages enable faster, higher resolution operation of industrial and medical imaging devices – including PET (positron emission tomography), PET-CT (computed tomography) and gamma cameras. The White Paper includes detail on performance and testing results from industry and new developments in Zecotek’s PET/MRI program.
“The Zecotek LFS technology, with its application specific variants, represents a significant breakthrough for existing and new applications in nuclear medicine, high energy physics and security, in particular when matched with our patented MAPD photo detection technologies,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “The rapid growth in demand for more sensitive, relatively low cost and robust scintillation materials also represents large new market opportunity for our LFS material. The high material yield of our proprietary crystal growth technology provides a clear cost advantage over competing scintillation crystals. In addition, recent tests substantiate the clear advantage of our patented LFS materials over other scintillation materials competing in the high-energy physics field due to improved radiation hardness of our high-performance LFS-3 crystal. This competitive advantage significantly increases the crystals life cycle as compared to existing material used in high-energy physics experiments.”
Solid-state scintillation crystals play a vital role in industrial, medical, fundamental research, and security, where they are used to convert high-energy photons into visible light. Zecotek’s scientists have pioneered research in high-performance scintillation detectors and maintain a comprehensive research program which has resulted in development of the patented LFS scintillation material. This very bright and very fast scintillation material was developed specifically for use in medical imaging systems, high-energy physics experiments, and other industrial applications. Zecotek’s LFS crystals are cost effectiveness, and have higher resolution and superior timing when compared to other existing materials.
In addition to their crucial function in medical PET machines, scintillation crystals are extensively used in particle physics experiments and in other environments where the detection hardware is exposed to very large doses of ionising radiation. Improvements in radiation hardness directly translate into fewer replacements of detector blocks and less frequent recalibration of detection systems. Zecotek’s LFS manufacturing technologies also permit the growth of very large-diameter boules with uniform properties and without cracking (a problem with many other competing materials), which secures a consistent and high element yield which also provides for lower unit costs, critical for the sale of PET scanners.
Robustness and radiation hardness of scintillation are factors that play a decisive role in controlling the costs of maintenance and the downtime of major experimental installations, such as the FAIR (Facility for Antiproton and Ion Research) particle accelerator in Darmstadt or in CERN’s Large Hadron Collider.
The White Paper details performance parameters and recent test results, and is available for viewing at : http://www.zecotek.com/media/LFS-White-Paper-June-2011.pdf.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 827-5212
CHF Investor Relations
Julia Clark, Account Manager
T: (416) 868-1079 x236
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.